

**AMENDMENTS TO THE CLAIMS**

The following listing of claims replaces all prior versions, and listings, of claims in this application.

Claims 1-20 (Canceled)

Claim 21 (Currently Amended): ~~The method of claim 20~~ A method of treating severe depression in a patient in need thereof, wherein the patient has a MADRS score of at least 29, the method comprising administering a daily pharmaceutically effective amount of escitalopram or a pharmaceutically acceptable salt thereof to the patient, wherein the daily dose of escitalopram or a pharmaceutically acceptable salt thereof is 10 mg or less.

Claim 22 (Canceled)

Claim 23 (Currently Amended): The method of claim 21, wherein the escitalopram or pharmaceutically acceptable salt thereof ~~daily dose~~ is administered daily to obtain a significant improvement ~~an effect~~ in the patient after one week as measured by the CGI improvement and severity subscale.

Claim 24 (Canceled)

Claim 25 (Previously Presented): The method of claim 21, wherein the daily dose is 10 mg of escitalopram or a pharmaceutically acceptable salt thereof.

Claim 26 (Canceled)

Claim 27 (Previously Presented): The method of claim 21, wherein the pharmaceutically acceptable salt is an oxalate salt.

Claim 28 (Canceled)

Claim 29 (Previously Presented): The method of claim 23, wherein the pharmaceutically acceptable salt is an oxalate salt.

Claim 30 (Canceled)

Claim 31 (Previously Presented): The method of claim 25, wherein the pharmaceutically acceptable salt is an oxalate salt.

Claim 32 (Canceled)

Claim 33 (Previously Presented): The method of claim 27, wherein the pharmaceutically acceptable salt is a crystalline oxalate salt.

Claim 34 (Canceled)

Claim 35 (Previously Presented): The method of claim 29, wherein the pharmaceutically acceptable salt is a crystalline oxalate salt.

Claim 36 (Canceled)

Claim 37 (Previously Presented): The method of claim 31, wherein the pharmaceutically acceptable salt is a crystalline oxalate salt.